Skip to main content
. 2020 Feb 15;12(2):478–492.

Figure 2.

Figure 2

FASSs promoted HUVEC tube formation and stabilized the neovasculature. A. FASSs promoted HUVEC tube length, node number, and branch length of the tubes in a dose-dependent manner. Magnification, 100×. B. FASSs promoted the release of proangiogenic factors from HUVECs in a dose-dependent manner. ELISA and RT-qPCR were performed on control (0) and FASSs-treated HUVECs. C. Representative immunofluorescence images of α-SMA expression in HUVECs after treatment with FASSs. Magnification, 400×. D. Western blot and RT-qPCR revealed that FASSs dose-dependently significantly increased expression of α-SMA and CD31 in HUVECs. *P<0.05, **P<0.01.